Minerva Neurosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Minerva Neurosciences, Inc. (NERV) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income1.44-30.01-32.11-49.911.94-72.18-50.17
Depreciation & Amortization0.020.010.010.100.180.160.02
Deferred Income Tax0.000.000.00-1.800.00-2.250.00
Stock Based Compensation1.331.974.115.229.700.000.00
Change in Working Capital-0.324.94-4.060.26-44.582.850.11
Change in Accounts Payable-0.200.84-0.880.86-1.320.000.00
Change in Other Working Capital-22.024.107.416.33-3.060.000.00
Other Operating Activities-22.028.287.416.338.7328.000.04
Net Cash from Operating Activities-19.55-14.78-24.65-24.60-33.82-43.43-41.94
Investing Activities
Capital Expenditures0.000.00-0.020.000.000.000.00
Purchases of Investments0.000.000.000.0024.530.000.00
Sales/Maturities of Investments0.000.000.000.0024.5314.0869.49
Net Cash from Investing Activities0.000.00-0.020.0024.5314.0869.49
Financing Activities
Debt Repayment0.000.000.000.000.000.00-4.00
Common Stock Issued0.0020.000.000.0012.550.000.00
Other Financing Activities0.00-0.400.0060.00-0.460.000.00
Net Cash from Financing Activities0.0019.600.0060.0013.240.52-3.34
Summary
Net Change in Cash-19.554.82-24.6635.403.94-28.8224.20
Cash at Beginning of Period41.0136.1960.8625.4621.5150.3326.13
Cash at End of Period21.46-14.7836.1960.8625.4621.5150.33
Free Cash Flow-19.55-14.78-24.66-24.60-33.82-43.43-41.94
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.000.09